Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1-mutated oral squamous cell carcinoma

Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1-mutated oral squamous cell carcinoma

Abstract. Background:. Oral squamous cell carcinoma (OSCC) is a prevalent type of cancer with a high mortality rate in its late stages. One of the major challenges in OSCC treatment is the resistance to epidermal growth factor receptor (EGFR) inhibitors. Therefore, it is imperative to elucidate the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yumeng Lin, Yibo Huang, Bowen Yang, You Zhang, Ning Ji, Jing Li, Yu Zhou, Ying-Qiang Shen, Qianming Chen, Xiangxiang Pan
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-08-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003217
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
by: Yueyang Wang, et al.
Published: (2025-08-01)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
by: Maicol Mancini, et al.
Published: (2017-12-01)

Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma
by: Fouzia Nawab, et al.
Published: (2025-08-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
by: Jiannong Li, et al.
Published: (2013-11-01)

The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma
by: Ismail Beypinar, et al.
Published: (2019-08-01)

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)

Mutational landscape and DNA methylation-based classification of squamous cell carcinoma and urothelial carcinoma
by: Min Ren, et al.
Published: (2025-06-01)

Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
by: Lianxi Song, et al.
Published: (2025-09-01)

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
by: Wengang Zhang, et al.
Published: (2025-05-01)

Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma
by: Mengting Liu, et al.
Published: (2025-11-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

New benzimidazole-triazole glycoconjugates as anti-cancer agents and EGFR inhibitors
by: Aladdin M. Srour, et al.
Published: (2025-07-01)

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis
by: Yanjing Guo, et al.
Published: (2025-07-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

The ROS/CaMK II/β-Catenin Signaling Axis Affects the Osteogenic Potential of BMSCs and Disrupts Implant Osseointegration: An In Vitro Study
by: Jiaqi Ding, et al.
Published: (2025-01-01)

Hypergravity-induced plastic alteration of the vestibulo-sympathetic reflex involves decrease in responsiveness of CAMK2-expressing neurons in the vestibular nuclear complex
by: Chikara Abe, et al.
Published: (2019-08-01)

Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma
by: Chenglin Zhang, et al.
Published: (2025-06-01)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
by: Yue Lu, et al.
Published: (2021-11-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

THE REASONS OF RESISTANCE TO THE TNF α INHIBITORS AND WAYS OF ITS OVERCOMING
by: E.I. Alexeeva, et al.
Published: (2009-11-01)

Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
by: Ryan Cooper, et al.
Published: (2024-11-01)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-03-01)

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
by: Marianna Peroni, MD, et al.
Published: (2025-08-01)

Detection of EGFR Mutations in Bronchial Wash from Iraqi patients with nonsmall Cell Lung Cancer (NSCLC)
by: Hayfa H. Hassani, et al.
Published: (2014-09-01)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
by: Huijuan Wang, et al.
Published: (2020-01-01)

CT-based radiomics analysis for predicting EGFR and ALK mutational status in non‑small cell lung cancer
by: Ruimin He, et al.
Published: (2025-07-01)

Integrated analysis of oral rinse-derived and plasma circulating tumour DNA for mutation profiling and outcome prediction with oral squamous cell carcinoma
by: Zhuo Chen, et al.
Published: (2025-06-01)

Dual Targeting of Inflammatory and Immune Checkpoint Pathways to Overcome Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma
by: Qu Z, et al.
Published: (2025-07-01)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
by: Sophia G Liva, et al.
Published: (2020-01-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer
by: Yongfeng Yu, et al.
Published: (2025-07-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

The targeting of AKR1C1 synergizes with gefitinib via the STAT3 signaling pathway in EGFR-mutated NSCLC
by: Linlin Chang, et al.
Published: (2025-11-01)

Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example
by: Malgorzata Marcinkowska, et al.
Published: (2010-01-01)

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer
by: Angela Abdollahi, et al.
Published: (2025-01-01)

Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors
by: Zhen Zheng, et al.
Published: (2017-05-01)